GlassScriptPhysician profile
James W Hansen
NPI 1275531212
$2,747.24
in general payments reported to CMS, 2019-2025
18 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $278 · 2021: $108 · 2022: $134 · 2023: $251 · 2024: $388 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.15 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,097.49 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $378.99 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.09 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $221.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $201.34 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Jazz Pharmaceuticals INC. | $199.09 | 2019-2025 | |
| Abbvie INC. | $80.83 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $47.20 | 2025 | Givlaari |
| Amgen INC. | $41.73 | 2019-2020 | |
| Pfizer INC. | $36.64 | 2019-2025 | |
| Philips North America LLC | $35.18 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $30.49 | 2019 | |
| Astellas Pharma US INC | $30.43 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $24.69 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $22.30 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $21.26 | 2019 | |
| Abbott Laboratories | $17.79 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.55 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.